San Francisco-based Apogee Therapeutics (Nasdaq: APGE) has announced a strategic financing collaboration with funds managed by Blackstone Life Sciences, providing up to USD 1.3 billion in non-dilutive capital to fund Phase III development and potential commercialization of zumilokibart (APG777), its anti-IL-13 monoclonal antibody. The deal was announced alongside the release of a new data update for zumilokibart from the APEX Phase II clinical trial.
The transaction is structured in two components. The first is a synthetic royalty arrangement under which Blackstone will provide up to USD 800 million in exchange for low-to-mid single digit tiered royalties on worldwide annual sales of zumilokibart over a 15-year term, with royalties declining at higher revenue thresholds and no royalties applying to global annual sales above USD 8 billion. The USD 800 million is disbursed across tranches: USD 100 million at signing, USD 100 million upon completion of Phase III enrollment, and USD 200 million upon positive Phase III data, totaling USD 400 million in pre-approval funding. An additional USD 400 million becomes available upon US FDA approval of zumilokibart, of which USD 150 million is at Apogee's option.
The funding agreement also includes provisions governing a change of control, with an option to repurchase a portion of the royalty. The second component is a senior corporate debt facility of up to USD 500 million, available at the mutual consent of both parties. No syndicate members or co-investors are named; Blackstone Life Sciences is the sole capital provider across both components.
Apogee stated that combined with its existing cash balance of USD 1.3 billion, the financing is intended to support operations through commercialization of zumilokibart without requiring additional equity issuance. The company has removed its prior cash runway end date guidance as a result of the transaction.
Company overview and pipeline
Apogee is a clinical-stage biotechnology company focused on inflammatory and immunology indications, with a pipeline of half-life extended antibodies designed to optimize dosing intervals relative to existing approved therapies. Zumilokibart, also designated APG777, is the company's most advanced asset and targets IL-13, a cytokine implicated in atopic dermatitis, asthma, and eosinophilic esophagitis.